Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI claim closely matches Injectafer labeling excerpts on symptomatic hypophosphatemia, including serious outcomes (osteomalacia/fractures), occurrence after one dose, and label-directed monitoring and treatment for at-risk patients and repeat courses within three months.
Category Scores
Accurate Statements
Symptomatic hypophosphatemia (including serious outcomes such as osteomalacia and fractures) has been reported in patients treated with Injectafer.
5.2 Symptomatic Hypophosphatemia: “Symptomatic hypophosphatemia with serious outcomes including osteomalacia and fractures requiring clinical intervention has been reported...”
Symptomatic hypophosphatemia can occur even after one dose.
5.2 Symptomatic Hypophosphatemia: “However, symptomatic hypophosphatemia has been reported after one dose.”
Patients at risk should have serum phosphate monitored before repeat courses/within 3 months.
5.2: “Monitor serum phosphate levels in patients at risk...” and “Check serum phosphate levels prior to a repeat course of treatment... and in any patient who receives a second course of therapy within three months...” plus 2.3: repeat course within three months monitoring.
Hypophosphatemia should be treated as medically indicated.
5.2: “Treat hypophosphatemia as medically indicated.” and 2.3: “Treat hypophosphatemia as medically indicated.”
Unsupported Statements
Contradictions
Important Omissions
The label lists specific possible risk factors for hypophosphatemia (e.g., GI disorders with malabsorption, inflammatory bowel disease, certain medication effects, hyperparathyroidism, vitamin D deficiency, malnutrition, HHT). The claim does not mention these risk factors.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated response accurately reflects on-label warning and monitoring guidance for symptomatic hypophosphatemia and does not introduce conflicting or unsafe instructions beyond the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Risk factors enumeration is omitted; the claim remains consistent with the label but is less complete than the full safety guidance.
Suggested Improvement
Optionally include that the label specifies examples of risk factors and that serum phosphate should be monitored in those at risk, including when repeat courses occur within three months.